Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emixustat - Kubota Vision

Next Previous
Drug Profile

Emixustat - Kubota Vision

Alternative Names: ACU-02; ACU-4429; ACU-4429 HCl; Emixustat HCl; Emixustat hydrochloride; RETAKU

Latest Information Update: 09 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acucela
  • Developer Kubota Vision; Otsuka Pharmaceutical
  • Class Cyclohexanes; Eye disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Retinoid isomerohydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stargardt disease
  • Phase II Diabetic retinopathy
  • Discontinued Dry age-related macular degeneration

Most Recent Events

  • 09 Dec 2024 Emixustat is still in phase III trials for Stargardt disease (In adolescents, In adults, In the elderly) in United Kingdom, Brazil, Denmark, Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA (PO) (NCT03772665)
  • 23 Jun 2022 Kubota Vision completes the phase III SeaSTAR trial in Stargardt disease in US, Brazil, Canada, Denmark, France, Germany, Italy, the Netherlands, South Africa, Spain and the UK (PO) (NCT03772665) (EudraCT2018-003498-82)
  • 09 Mar 2022 Emixustat is still in phase III trials for Stargardt disease (In adolescents, In adults, In the elderly) in United Kingdom, Brazil, Denmark, Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA (PO) (NCT03772665)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top